Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 30;15(1):336.
doi: 10.1186/s13023-020-01618-y.

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study

Affiliations

Diagnostic journey and impact of enzyme replacement therapy for mucopolysaccharidosis IVA: a sibling control study

Can Ficicioglu et al. Orphanet J Rare Dis. .

Abstract

Background: Mucopolysaccharidosis (MPS) IVA, also known as Morquio A syndrome, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Early recognition, diagnosis, and treatment of this progressive, multisystem disease by enzyme replacement therapy (ERT) can lead to improved outcomes and reduced mortality.

Methods: This report documents the diagnostic journey and treatment with ERT of three siblings with MPS IVA. Clinical outcome measures included growth, endurance, imaging, cardiac, respiratory, ophthalmology, and laboratory evaluations.

Results: Three siblings, diagnosed at 14.7, 10.1, and 3.2 years of age, demonstrated clinical improvement with weekly infusions of 2.0 mg/kg elosulfase alfa (Vimizim®, BioMarin Pharmaceutical, Novato, CA, USA). Patient 1 (oldest sibling) and Patient 2 (middle sibling) experienced a diagnostic delay of 8 years 7 months and 4 years after symptom onset, respectively. All three patients demonstrated improvements in growth, 6-min walk distance, joint range of motion, and respiratory function after 30 months of ERT. The treatment was well tolerated without any adverse events.

Conclusions: This case series highlights the importance of early recognition of the clinical and imaging findings that are initially subtle in MPS IVA. Early treatment with ERT is necessary to slow irreversible disease progression and improve patient outcomes. The oldest sibling experienced improvements in mobility despite severe symptoms resulting from a late diagnosis. When evaluating patients with skeletal anomalies, imaging multiple body regions is recommended. When findings such as anterior beaking of vertebrae or bilateral femoral head dysplasia are present, MPS IVA should be included in the differential diagnosis. Newborn screening must be considered for early detection, accurate diagnosis, and initiation of treatment to reduce morbidity.

Keywords: Anterior beaking; Diagnosis; Enzyme replacement therapy; Mucopolysaccharidosis IVA; Platyspondyly; Treatment.

PubMed Disclaimer

Conflict of interest statement

Can Ficicioglu, MD, PhD, has served as an advisor or consultant for: Genzyme, Horizon, Orphan Tech., Recordati, Shire, and Sobi. He received grants for clinical research from: Genzyme, Orphan Tec, RegenxBio, Takeda, and Vtesse. Dena R. Matalon, MD, none. Nicole Luongo, PA-C, none. Caitlin Menello, CGC,, none. Tracy Kornafel,, none. Andrew J. Degnan, MD, none.

Figures

Fig. 1
Fig. 1
Anteroposterior radiograph of hips and pelvis in Patient 1 at 6 years of age shows bilateral sclerotic, fragmented, and flattened proximal femoral epiphyses (asterisks), irregular acetabula (arrowheads), and coxa valga deformities. The patient was initially diagnosed with Legg–Calve–Perthes disease; in retrospect, acetabular irregularities and coxa valga would not be typical in this condition
Fig. 2
Fig. 2
Representative serial radiographs of the proximal right femur of Patient 1 over time show progressive flattening of the epiphysis, concomitant widening of the proximal metaphyses, and increased irregularity of the acetabula resulting in compensatory pseudarthrosis-like formation
Fig. 3
Fig. 3
Lateral radiographs and MRIs of the thoracic spine in the three siblings. a In Patient 1, lateral thoracic spine radiograph (left) at 10 years of age shows relatively moderate vertebral body height loss (platyspondyly) and anterior vertebral body beaking, most prominent in the mid-to-lower thoracic spine (arrowheads). Sagittal T2-weighted MRI of the thoracic spine (right) shows moderate platyspondyly with prominent anterior beaking of multiple thoracic and upper lumbar vertebral bodies (arrowheads). The patient was initially diagnosed with spondyloepiphyseal dysplasia on the basis of clinical presentation, platyspondyly, and femoral epiphyseal abnormalities on imaging, although anterior beaking in the middle third of the spine is highly suggestive of MPS IVA, and vertebral flattening is not as prominent as would be expected in spondyloepiphyseal dysplasia. b In Patient 2, lateral thoracic spine radiograph at 6 years of age (left) shows anterior beaking of multiple thoracic vertebral bodies (arrowheads). Sagittal T2-weighted MRI of the thoracic spine at 10 years of age (right) shows anterior vertebral body beaking (arrowheads) with mild vertebral height loss without platyspondyly. Presence of anterior vertebral body beaking in this case is strongly suggestive of MPS IVA. c In Patient 3, lateral thoracic spine radiograph at 3 years of age (left) shows anterior beaking of multiple thoracic vertebral bodies without significant vertebral body height loss. Sagittal T2-weighted MRI of the thoracic spine at 5 years of age (right) highlights anterior vertebral body beaking. As with this patient’s siblings, anterior vertebral body beaking supported the diagnosis of MPS IVA
Fig. 4
Fig. 4
Sagittal T2-weighted TSE MRI of the cervical spine of Patient 1 at 10 years of age shows dysplastic odontoid process of C2, with irregular sclerosis and posterior migration of the tip of the dens (asterisk)
Fig. 5
Fig. 5
Radiographic features of the hand in the three siblings supportive of MPS IVA. a Patient 1 at 6 years of age showed prominent shortening of the fourth and fifth metacarpals (asterisks) with proximal pointing of the fifth metacarpal (arrowhead) and widening of the first metacarpal. b Patient 2 at 6 years of age showed proximal pointing of the fifth metacarpal (arrowhead) and irregular carpal bones (asterisk). Notably, this patient’s metacarpal abnormalities were much less conspicuous compared with those of his older brother (Patient 1) at the same age. c Patient 3 at 3 years of age showed proximally shortened, widened metacarpals with proximal pointing of the second and fifth metacarpals (arrowheads)
Fig. 6
Fig. 6
Physical examination of the siblings. Patient 1 at 14 years of age, Patient 2 at 9 years of age, and Patient 3 at 3 years of age. Lordotic posture can be noted in all three patients. Prior to starting ERT, all three siblings showed skeletal abnormalities and walking impairment, which were more advanced in the oldest sibling (Patient 1)

Similar articles

Cited by

References

    1. Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, Borgo A, Braunlin E, Eto Y, Gold JI. Recommendations for the management of MPS IVA: systematic evidence-and consensus-based guidance. Orphanet J Rare Dis. 2019;14(1):137. doi: 10.1186/s13023-019-1074-9. - DOI - PMC - PubMed
    1. Tomatsu S, Yasuda E, Patel P, Ruhnke K, Shimada T, Mackenzie WG, Mason R, Thacker MM, Theroux M, Montaño AM. Morquio A syndrome: diagnosis and current and future therapies. Pediatr Endocrinol Rev. 2014;12(1):141. - PMC - PubMed
    1. Yasuda E, Fushimi K, Suzuki Y, Shimizu K, Takami T, Zustin J, Patel P, Ruhnke K, Shimada T, Boyce B. Pathogenesis of Morquio A syndrome: an autopsied case reveals systemic storage disorder. Mol Genet Metab. 2013;109(3):301–311. doi: 10.1016/j.ymgme.2013.04.009. - DOI - PubMed
    1. Matalon R, Arbogast B, Dorfman A. Deficiency of chondroitin sulfate N-acetylgalactosamine 4-sulfate sulfatase in Maroteaux–Lamy syndrome. Biochem Biophys Res Commun. 1974;61(4):1450–1457. doi: 10.1016/S0006-291X(74)80446-8. - DOI - PubMed
    1. Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology. 2011;50(suppl_5):v4–v12. doi: 10.1093/rheumatology/ker394. - DOI - PubMed

Publication types

LinkOut - more resources